FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592960494> ?p ?o ?g. }

• W2592960494 endingPage "440" @default.
• W2592960494 startingPage "433" @default.
• W2592960494 abstract "Background Few data are available regarding efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel in advanced breast cancer patients outside a controlled trial, especially for the weekly schedule. Patients and Methods We prospectively collected data of advanced breast cancer patients who were candidates to be treated with weekly (125 mg/m2 for 3 consecutive weeks followed by a 1-week rest) or every 3 weeks (260 mg/m2) schedules of nab-paclitaxel, according to physician's decision. Results The study enrolled 209 patients, of whom 92 (39.3%) received weekly nab-paclitaxel. The median age was 58 (range, 31-84) years; 21.8% of the patients were classified as triple-negative breast cancer (estrogen-recetor/progesteron-receptor-negative). The median number of cycles was 5.5. The overall response rate was 32.1% in the whole population, without any significant difference according to schedule, previous paclitaxel exposure, presence of visceral metastases, or line of treatment. The median time to disease progression was 6 months (95% confidence interval, 1-34), with no differences according to the schedule of treatment. Severe adverse events (Grade 3-4) were observed in 60.6% of the patients. The main toxicities were alopecia (53.4%), neutropenia (3%), and sensory neuropathy (2.1%). Conclusion Our real-life data indicate that both schedules of nab-paclitaxel are manageable and safe in advanced breast cancer patients, even if previously treated with other taxanes." @default.
• W2592960494 created "2017-03-16" @default.
• W2592960494 creator A5001234328 @default.
• W2592960494 creator A5010972450 @default.
• W2592960494 creator A5026022049 @default.
• W2592960494 creator A5038264203 @default.
• W2592960494 creator A5038515367 @default.
• W2592960494 creator A5045450050 @default.
• W2592960494 creator A5049288507 @default.
• W2592960494 creator A5065811790 @default.
• W2592960494 creator A5066189149 @default.
• W2592960494 creator A5066455981 @default.
• W2592960494 creator A5074566193 @default.
• W2592960494 creator A5089288192 @default.
• W2592960494 date "2017-10-01" @default.
• W2592960494 modified "2023-10-18" @default.
• W2592960494 title "Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials" @default.
• W2592960494 cites W1789924039 @default.
• W2592960494 cites W1984119576 @default.
• W2592960494 cites W1995153811 @default.
• W2592960494 cites W2022678011 @default.
• W2592960494 cites W2099173339 @default.
• W2592960494 cites W2117972559 @default.
• W2592960494 cites W2123528875 @default.
• W2592960494 cites W2153017356 @default.
• W2592960494 cites W2158133583 @default.
• W2592960494 cites W2163003060 @default.
• W2592960494 cites W2178665864 @default.
• W2592960494 cites W2264815585 @default.
• W2592960494 cites W2586196337 @default.
• W2592960494 doi "https://doi.org/10.1016/j.clbc.2017.03.004" @default.
• W2592960494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28366406" @default.
• W2592960494 hasPublicationYear "2017" @default.
• W2592960494 type Work @default.
• W2592960494 sameAs 2592960494 @default.
• W2592960494 citedByCount "6" @default.
• W2592960494 countsByYear W25929604942018 @default.
• W2592960494 countsByYear W25929604942020 @default.
• W2592960494 countsByYear W25929604942021 @default.
• W2592960494 countsByYear W25929604942023 @default.
• W2592960494 crossrefType "journal-article" @default.
• W2592960494 hasAuthorship W2592960494A5001234328 @default.
• W2592960494 hasAuthorship W2592960494A5010972450 @default.
• W2592960494 hasAuthorship W2592960494A5026022049 @default.
• W2592960494 hasAuthorship W2592960494A5038264203 @default.
• W2592960494 hasAuthorship W2592960494A5038515367 @default.
• W2592960494 hasAuthorship W2592960494A5045450050 @default.
• W2592960494 hasAuthorship W2592960494A5049288507 @default.
• W2592960494 hasAuthorship W2592960494A5065811790 @default.
• W2592960494 hasAuthorship W2592960494A5066189149 @default.
• W2592960494 hasAuthorship W2592960494A5066455981 @default.
• W2592960494 hasAuthorship W2592960494A5074566193 @default.
• W2592960494 hasAuthorship W2592960494A5089288192 @default.
• W2592960494 hasConcept C121608353 @default.
• W2592960494 hasConcept C126322002 @default.
• W2592960494 hasConcept C143998085 @default.
• W2592960494 hasConcept C197934379 @default.
• W2592960494 hasConcept C2775930923 @default.
• W2592960494 hasConcept C2776694085 @default.
• W2592960494 hasConcept C2777063308 @default.
• W2592960494 hasConcept C2777292972 @default.
• W2592960494 hasConcept C2777511904 @default.
• W2592960494 hasConcept C2908647359 @default.
• W2592960494 hasConcept C44249647 @default.
• W2592960494 hasConcept C530470458 @default.
• W2592960494 hasConcept C71924100 @default.
• W2592960494 hasConcept C99454951 @default.
• W2592960494 hasConceptScore W2592960494C121608353 @default.
• W2592960494 hasConceptScore W2592960494C126322002 @default.
• W2592960494 hasConceptScore W2592960494C143998085 @default.
• W2592960494 hasConceptScore W2592960494C197934379 @default.
• W2592960494 hasConceptScore W2592960494C2775930923 @default.
• W2592960494 hasConceptScore W2592960494C2776694085 @default.
• W2592960494 hasConceptScore W2592960494C2777063308 @default.
• W2592960494 hasConceptScore W2592960494C2777292972 @default.
• W2592960494 hasConceptScore W2592960494C2777511904 @default.
• W2592960494 hasConceptScore W2592960494C2908647359 @default.
• W2592960494 hasConceptScore W2592960494C44249647 @default.
• W2592960494 hasConceptScore W2592960494C530470458 @default.
• W2592960494 hasConceptScore W2592960494C71924100 @default.
• W2592960494 hasConceptScore W2592960494C99454951 @default.
• W2592960494 hasIssue "6" @default.
• W2592960494 hasLocation W25929604941 @default.
• W2592960494 hasLocation W25929604942 @default.
• W2592960494 hasOpenAccess W2592960494 @default.
• W2592960494 hasPrimaryLocation W25929604941 @default.
• W2592960494 hasRelatedWork W181195935 @default.
• W2592960494 hasRelatedWork W1996698721 @default.
• W2592960494 hasRelatedWork W2020150632 @default.
• W2592960494 hasRelatedWork W2024155108 @default.
• W2592960494 hasRelatedWork W2071730404 @default.
• W2592960494 hasRelatedWork W2154590531 @default.
• W2592960494 hasRelatedWork W2415253097 @default.
• W2592960494 hasRelatedWork W2592505613 @default.
• W2592960494 hasRelatedWork W2688575822 @default.
• W2592960494 hasRelatedWork W3009079691 @default.
• W2592960494 hasVolume "17" @default.
• W2592960494 isParatext "false" @default.

• next